Trevi Therapeutics Inc — Cash Flow (NASDAQ:TRVI) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Cash from operating activities 29 M28.95 M28.18 M31.71 M38.26 M 44.01 M Cash from investing activities 32 K32 K107.37 M59.43 M21.53 M 82.68 M Cash from financing activities 16.72 M20.77 M111.31 M7.91 M61.48 M 172.2 M Free cash flow 28.97 M28.95 M28.02 M31.57 M38.22 M 44.01 M

Haberler

Trevi’nin nalbuphine ER ilacı IPF öksürüğünde önemli azalma gösterdi

Trevi’s nalbuphine ER shows significant reduction in IPF cough

Trevi Therapeutics kronik öksürük programı için FDA toplantısı planladı

Trevi Therapeutics schedules FDA meeting for chronic cough program

Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Canadian Solar (NASDAQ:CSIQ), Elme (NYSE:ELME)

Stifel, Trevi Therapeutics’in öksürük ilacı potansiyeli nedeniyle hedef fiyatını 18 dolara yükseltti

Trevi Therapeutics stock price target raised to $18 by Stifel on cough drug potential

Trevi Therapeutics hisseleri 14,01 dolar ile tüm zamanların en yüksek seviyesine ulaştı

Trevi Therapeutics stock hits all-time high of 14.01 USD

Trevi Therapeutics, David Hastings’ı yeni CFO olarak atadı

Trevi Therapeutics appoints David Hastings as new CFO

Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And More (TRVI)